Low-dose sodium oxybate for idiopathic hypersomnia sleepiness
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old and have a primary diagnosis of idiopathic hypersomnia (IH) that fits the study’s sleep-disorder criteria
- Your body mass index (BMI) is between 18 and 35
- Most days you sleep at least 9 hours (including naps), based on at least 10 of 14 days of a sleep diary
- You score at least 10 on the Epworth Sleepiness Scale (done at pre-screening)
- A sleep specialist has recommended low-dose sodium oxybate (LSO) as part of usual care, and you agree to delay it until baseline tests are finished
- If you take wake-promoting medicines or antidepressants, your dose must be stable for at least 2 months before starting and stay stable during the main study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how narcolepsy or idiopathic hypersomnia affects thinking and cardiovascular health, and how usual treatment medications may change those outcomes. It may help researchers understand risks and benefits of common hypersomnia therapies.
This study tests whether a low-sodium form of oxybate can reduce symptoms like dizziness, rapid heartbeat, and fatigue in people with both idiopathic hypersomnia and POTS. If you have these two conditions and haven't tried oxybate before, this trial may be a good fit.
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
This trial tests a new medicine called ALKS 2680 for people with Idiopathic Hypersomnia (a condition that causes extreme sleepiness without a clear cause). The goal is to see if it is safe and effective at helping you stay awake during the day.
This study tests an investigational medication called TAK-360 for people with idiopathic hypersomnia (IH), a sleep disorder that causes excessive daytime sleepiness. The goal is to see if the drug can help reduce sleepiness and improve daily function.
This trial tests a medication, solriamfetol, to see if it helps people with idiopathic hypersomnia stay awake during the day. It may be an option if you have trouble staying awake despite getting enough sleep at night.
Hear when a new Idiopathic Hypersomnia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.